Euractiv (Partner Content)
EU Perspectives
European Biotechnology Magazine
APM Market Access
EURACTIV - UCB is the only company headquartered in the European Union among the nine drugmakers that signed Donald Trump's most-favoured-nation pricing plan on Monday, 31 August. Its new US factory will not come at Europe's expense, the Brussels-based company said. Read more
EU PERSPECTIVES - Europe's top life sciences investors have welcomed the EU's new €5bn Scaleup Europe Fund. One of its own backers, Novo Holdings, has just put €500m into it. Yet the same investors told EU Perspectives the fund will barely touch their sector's real funding problem. Read more
EURACTIV - Hungarian universities remain barred from the EU's flagship Horizon research programme, it has no national dementia plan, and the diagnostic infrastructure the new drugs depend on barely exists. Read more
EU PERSPECTIVES - Tariff threats are working, the president declared, crediting them with forcing pharma companies and foreign governments to accept his most-favoured-nation pricing plan. Instead of driving prices sharply lower in the US, however, it could push them up for everyone else. Read more
